Recursion PharmaceuticalsRXRX

Key highlights

• Spending guidance lowered: The company reduced its full year cash operating expense guidance to $375 million, down from the previous forecast of $390 million, as it finds more ways to run its labs efficiently. This is the primary driver of the company's plan to keep its $556.8 million in total cash available to fund operations into early 2028.
• Strategic milestone achieved: Partner Genentech advanced its first neuroscience drug target into a discovery program, proving that Recursion's AI can find viable paths in complex brain diseases. To date, this single partnership has generated $216 million in payments for Recursion and includes up to 40 potential drug programs that could each pay out over $300 million if they succeed.
• Revenue decline explained: Total revenue fell to $7.7 million compared to $19.2 million a year ago, because the company successfully finished several project phases in the prior period that are not repeating now. This drop is common for young biotech firms that rely on lumpy payments from large partners rather than steady product sales.
• Losses narrowing: The quarterly net loss improved to $131.0 million from $171.9 million last year, largely because research and development costs fell by $39 million. This lower spending was driven by improved efficiency in the labs and a $19.6 million reduction in payments for external oncology data.
• Clinical trials accelerating: The company expects to start its Phase 1 2 clinical trial for a new oncology drug called REC-7735 in the second half of 2026. Management also expects to provide a path for the potential approval of its lead drug for a rare colon disease in the second half of 2026, which could move it closer to its first commercial product.

Our take: A productive quarter that proves the technology is working where it matters most. While the revenue miss looks sharp, the milestone from Genentech and the reduced spending guidance show a more disciplined path to commercial success. This progress strengthens the long-term case that Recursion can successfully discover drugs using AI.